Lilly agrees to acquire Orna Therapeutics in an all-cash deal.

“For many cell-based therapies, progress comes from connecting the right pieces at the right moment,” Klein said. “When ...

Eli Lilly (LLY) stock acquiring Orna Therapeutics for up to $2.4 billion to develop circular RNA CAR-T therapies for B ...

EB103 utilizes Eureka’s ARTEMIS technology, a platform designed to harness the human immune system more effectively than standard therapies. The ARTEMIS T cells are engineered to address the specific ...

A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients with severe, treatment-refractory systemic lupus erythematosus.

Frost & Sullivan has conducted comprehensive research on the cell therapy industry and published the "Cell Therapy's Full-Chain Integration and Commercial Acceleration". The in-depth report aims to ...

A new generation of engineered immune cell destroys cancer cells in mice 1 as effectively as conventional CAR-T-cell ...

More than 1 million Americans live with the neurodegenerative brain disorder – and that number is expected to climb ...

A new study led by researchers at the UNC School of Medicine and Cartesian Therapeutics, found that immunotherapy can help ...

Catalent made a series of deals early this decade to build up its presence in Gosselies. Now, it's planning to wind down cell ...

Charles River Laboratories is continuing its run of layoffs by announcing the closure of its cell therapy contract development and manufacturing organization (CDMO) site in Hanover, Maryland that will ...